Abstract
Patient-derived xenograft (PDX) models for cancer research have recently attracted considerable attention in both the academy and industry (Hidalgo et al., 2014; Wilding and Bodmer, 2014). PDX models have been developed from different tumor types including lung cancer to improve the drug development process. These models are used for pre-clinical drug evaluation and can be used for the predictive results of clinical outcomes because they conserve original tumor characteristics such as heterogeneity, complexity and molecular diversity (Kopetz et al., 2012). Additionally, PDX model provides the potential tool for the personalized drug therapy. In this protocol, we present methods for the establishment of PDX in mice using primary tumor tissues from patients with small cell lung cancer (SCLC).
Materials and Reagents
Equipment
Procedure
Notes
Acknowledgments
We thank Dr. Taofeek K. Owonikoko, Assistant Professor and Guojing Zhang, Research Specialist at Emory University for providing primary lung tumor tissues. This work is supported by NCI, National Institutes of Health grants 1R01CA193828, 2R01CA136534 and 1R01CA200905-01A1.
References
If you have any questions/comments about this protocol, you are highly recommended to post here. We will invite the authors of this protocol as well as some of its users to address your questions/comments. To make it easier for them to help you, you are encouraged to post your data including images for the troubleshooting.